MEDICATION SHEET

SCOPE: ALS, CCT	
MEDICATION:	**ROCURONIUM BROMIDE (Zemuron)**
INTERVENTION:	Classification: Non-depolarizing neuromuscular blocking agent Actions: Neuromuscular blocking agent (NMBA) with competitive binding to the ACH receptors resulting in the absence of fasciculations; inhibits transmission of nerve impulses by binding with cholinergic receptors sites, antagonizing action of acetylcholine Contraindications: • Hypersensitivity Precautions: • Rocuronium may be associated with increased pulmonary vascular resistance; Caution should be used patients with pulmonary hypertension or valvular heart disease Dosage: I. RSI Paralytic: a. Adult/Pediatric: i. IV/IO: 1.5 mg/kg II. Continued Paralysis (Intubated): a. Adult/Pediatric: i. IV/IO: 0.1-0.2 mg/kg PRN Onset of Action: 1-2 minutes Duration: 30-45 minutes Adverse Effects: Minimal reported, however with small frequency: bradycardia, tachycardia Special Considerations: I. In RSI, care must be taken to prepare for the inevitable assuring a backup plan is at the ready II. Rocuronium has a longer duration of action than all ASL induction agents therefore post intubation management follow up for pain and anxiolysis management is a priority